trending Market Intelligence /marketintelligence/en/news-insights/trending/tMD2cwSGsqLRONqu45bz3Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Portola secures $50M loan from Bristol-Myers Squibb, Pfizer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Portola secures $50M loan from Bristol-Myers Squibb, Pfizer

Bristol-Myers Squibb Co. and Pfizer Inc. are lending $50 million to Portola Pharmaceuticals Inc. to help advance AndexXa, the company's potential antidote for Factor Xa inhibitors.

Bristol-Myers and Pfizer will each loan $25 million, the principal and interest of which will be repaid through royalties on AndexXa's commercial sales.

Portola is targeting regulatory approval of the drug in 2017, which is currently ongoing phase 3b/4 in patients with Factor Xa inhibitor-associated acute major bleeding.

Bristol-Myers Squibb and Pfizer have been collaborating with Portola Pharmaceuticals on the drug in exchange for rights in certain countries.